Monitoring of CD3+ T-cell count in patients receiving antithymocyte globulin induction after cadaveric renal transplantation
Transplantation Proceedings, cilt.45, sa.3, ss.929-931, 2013 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Özet
- Cilt numarası: 45 Sayı: 3
- Basım Tarihi: 2013
- Doi Numarası: 10.1016/j.transproceed.2013.02.092
- Dergi Adı: Transplantation Proceedings
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.929-931
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Aim: Although antithymocyte globulin (ATG) has been used for years, its ideal dose and administration period is obscure. Herein, we sought to use the CD3+ cell count to detect the optimal ATG dosage. Material and Methods: Twenty-one patients who underwent cadaveric donor renal transplantation from January 2009 to January 2012 received a 1 mg/kg ATG initial dose at the time of the operation. Patients were randomized into 2 cohorts. Group 1 (n = 11) received ATG according to the clinical and total lymphocyte count and group 2 (n = 10), the dose was tailored according to the CD3+ cell count. We compared the total and daily ATG dosages, ATG administration period, side effects of ATG, the number of days to a serum creatinine level <2 mg/dL, graft function at 3 months, acute rejection episodes, infection rates, costs of CD3+ analysis, and ATG amounts. Results: Both groups showed similar gender, age, and human leukocyte antigen matching data. There was no difference in presensitizing events or panel-reactive antibody class 1 and 2 levels. The number of days to a serum creatinine level of <2 mg/dL was 11 ± 1.5 for group 1 versus 10.4 ± 0.8 for group 2 (P =.45). Between groups 1 and 2, there was a significant difference between the mean total (P =.031) and mean daily ATG dosages (P =.006). We used a total dose of 3800 mg ATG for group 1 and 2200 mg for group 2 and for the group 2 who underwent 43 CD3+ cell counts. The expenditure per patient was 20% higher among group 1 than group 2. Conclusion: Determination of appropriate ATG dosages by CD3+ cell counts was useful, reliable, and cost effective. © 2013 Elsevier Inc.